Infect Chemother.
2024 Mar;56(1):96-97. 10.3947/ic.2023.0114.
Response to A Korean Post-Marketing Study of Abacavir/Dolutegravir/ Lamivudine in Patients with HIV-1
- Affiliations
-
- 1Department of Community and Family Medicine, All India Institute of Medical Sciences, Deoghar, Jharkhand, India
- 2Department of ECE, SR University, Warangal, Telangana State, India
- KMID: 2554985
- DOI: http://doi.org/10.3947/ic.2023.0114
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1
- A Korean Post-Marketing Surveillance Study of Dolutegravir Single-Agent Tablets in Patients with HIV-1
- Similar Durability of Two Single Tablet Regimens, Dolutegravir/Abacavir/Lamivudine and Elvitegravir/Cobicistat/Tenofovir/Emtricitabine: Single Center Experience
- Safety and Effectiveness Analysis of Kivexa® (lamivudine/abacavir sulfate) in Human Immunodeficiency Virus Infected Korean Patients
- Alopecia Areata Associated with Abacavir Therapy
